Copertina

Baseline Genomic Features in BRAFV600-Mutated Metastatic Melanoma Patients Treated with BRAF Inhibitor + MEK Inhibitor in Routine Care - DATASET

Fuente: Zenodo

Salvato in:

Dettagli Bibliografici
Autori principali:	Louveau, Baptiste, lebbe, celeste, Mourah, Samia
Natura:	Recurso digital
Pubblicazione:	Zenodo 2019
Accesso online:	Acceder al recurso
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi

Impact of Drug–Drug Interactions on Clinical Outcomes in Metastatic Melanoma Patients Treated With Combined BRAF/MEK Inhibitors: A Real‐World Study
di: Silvia Mezi, et al.
Pubblicazione: (2025)

Neutrophilic Panniculitis Secondary to BRAF and MEK Inhibitor Therapy to Treat Stage IIIa Cutaneous Melanoma
di: Tyra Reed, et al.
Pubblicazione: (2025)

C‐Terminal Hsp90 Inhibitors Overcome MEK and BRAF Inhibitor Resistance in Melanoma
di: Chitra Subramanian, et al.
Pubblicazione: (2025)

MEK Pathway Inhibitor‐Mediated Response in BRAF V600‐Mutant Melanoma with Brain Parenchymal and Leptomeningeal Metastases
di: Saud Alhusaini, et al.
Pubblicazione: (2024)

Metastatic Duodenal and Jejunal Melanoma With BRAF V600K Mutation
di: Taranjit Kaur, et al.
Pubblicazione: (2026)

Tretinoin synergistically enhances the antitumor effect of combined BRAF, MEK, and EGFR inhibition in BRAFV600E colorectal cancer
di: Yuya Yoshida, et al.
Pubblicazione: (2024)

Doxycycline Prophylaxis in Adolescent Patients Treated With MEK Inhibitors
di: Faith Cormier, et al.
Pubblicazione: (2025)

A Case of Melanoma of the Glans With BRAF V600E Mutation Successfully Treated With Dabrafenib and Trametinib
di: Hiroyuki Watanabe, et al.
Pubblicazione: (2026)

Brugada Phenocopy Induced by BRAF and MEK Inhibitors in a Lung Adenocarcinoma
di: Leonardo Portolan, et al.
Pubblicazione: (2024)

Ocular Safety and Visual Acuity Stability in Pediatric Patients With Optic Pathway Gliomas and Orbital Plexiform Neurofibromas Treated With BRAF and MEK Inhibitors
di: Aviv Sever, et al.
Pubblicazione: (2025)

Novel TEAD1 Inhibitor VT103 Enhances Dabrafenib Efficacy in BRAFV600E Mutated Lung Adenocarcinoma via Survivin Downregulation
di: Kazutaka Hosoya, et al.
Pubblicazione: (2025)

Clinical and Radiometabolic Correlatives of ddPCR Liquid Biopsy for BRAF V600 Mutated Melanoma
di: Ronen Stoff, et al.
Pubblicazione: (2026)

Successful Management of Suspected Epstein–Barr Virus‐Associated Hemophagocytic Lymphohistiocytosis in BRAF ‐Mutant Cholangiocarcinoma Following Treatment With Immune Checkpoint Inhibitors and BRAF / MEK Inhibitors: A Case Report
di: Akira Shibata, et al.
Pubblicazione: (2026)

Effects of Vemurafenib ± Cobimetinib on Intratumoral and Host Immunity in Patients With BRAFV600 Mutant Melanoma: Implications for Combination With Immunotherapy
di: Suthee Rapisuwon, et al.
Pubblicazione: (2026)

Phytochemicals From Houttuynia cordata Thunb as Potential Inhibitors of BRAF, MEK, and ERK: Insights From Molecular Docking
di: Mongkol Yanarojana, et al.
Pubblicazione: (2025)

Structure‐Based Pharmacophore Modeling, Virtual Screening, and Molecular Dynamics Simulation for the Discovery of Novel BRAF(V600E) Inhibitors in Melanoma Cancer
di: Salma Boulahia, et al.
Pubblicazione: (2026)

Cardiotoxicity of BRAF/MEK inhibitors
di: Katharina Seuthe, et al.
Pubblicazione: (2026)

Primary Sweat Gland Adenocarcinoma of the Skin With ATL2::PRKD3 Fusion: A Potential Cutaneous Analog of Cribriform Adenocarcinoma of the Salivary Glands?
di: Anaïs Brunet, et al.
Pubblicazione: (2025)

Cutaneous Adverse Drug Reactions Associated With BRAF and MEK Inhibitors: A Real‐World Analysis of WHO Pharmacovigilance Data
di: Natalia Sauer, et al.
Pubblicazione: (2026)

Predicting BRAF Mutations in Cutaneous Melanoma Patients Using Neural Network Analysis
di: Oleksandr Dudin, et al.
Pubblicazione: (2024)

Prognostic Potential of Baseline Eosinophils at the Initiation of Immune Checkpoint Inhibitor Treatment of Metastatic Melanoma: A Systematic Review and Meta‐Analysis
di: Thilo Gambichler, et al.
Pubblicazione: (2025)

BRAFV600E immunohistochemistry can reliably substitute BRAF molecular testing in the Lynch syndrome screening algorithm in colorectal cancer
di: Federica Grillo, et al.
Pubblicazione: (2024)

Real‐World Efficacy and Safety of MEK Inhibitor for Patients With Advanced NRAS ‐Mutant Melanoma: A Single‐Center Retrospective Study in Japan
di: Eiji Nakano, et al.
Pubblicazione: (2025)

Diclofenac Enhances the Response of BRAF Inhibitor to Melanoma Through ROS/p38/p53 Signaling
di: Haihong Qin, et al.
Pubblicazione: (2025)

Transsulfuration Reprogramming: A Metabolic Driver of BRAF‐V600E Resistance in Melanoma
di: Juntong Chen, et al.
Pubblicazione: (2025)

Design and Synthesis of Novel MEK Inhibitors for the Treatment of Solid Tumors
di: Jingting Zeng, et al.
Pubblicazione: (2025)

BRAF/MEK inhibitor rechallenge in advanced melanoma patients
di: Olivier J. Van Not, et al.
Pubblicazione: (2024)

Development of Poliosis in Patients Treated With Immunotherapy for Metastatic Cutaneous and Non‐Cutaneous Melanoma
di: Kimberly Smart, et al.
Pubblicazione: (2026)

Atypical Dermatophytosis in Patients Treated by JAK Inhibitors
di: Jen A. Barak Levitt, et al.
Pubblicazione: (2026)

Dissecting the Spectrum of Rare BRAF Mutations in Melanoma: A Nation‐Wide Study by the Italian Melanoma Intergroup ( IMI )
di: Bruna Dalmasso, et al.
Pubblicazione: (2026)

BRAFV600E mutation mediates invasive and growth features in ameloblastoma
di: Chen‐Xi Zhang, et al.
Pubblicazione: (2024)

Synovial Sarcoma With BRAF V600E Mutation: A Case Report and Literature Review
di: Tian Gao, et al.
Pubblicazione: (2026)

Identification of a Novel Non-V600E BRAF Mutation in Papillary Thyroid Cancer
di: Marco Capezzone, et al.
Pubblicazione: (2024)

Clinical benefit from palbociclib, letrozole and goserelin combination therapy for sweat gland carcinoma with neuroendocrine differentiation (SCAND)
di: Sofia Tzoumpa, et al.
Pubblicazione: (2024)

Neoadjuvant BRAF and MEK inhibitor therapy elicits pathological complete response in stage IIIA non‐small cell lung cancer harboring BRAF V600E mutation: A case report
di: Zhicheng Huang, et al.
Pubblicazione: (2024)

GPX4 Inhibitor Resistance and Metastatic Features in Triple‐Negative Breast Cancer
di: Marie Sabatier, et al.
Pubblicazione: (2026)

Clinical characteristics of mycosis fungoides with angiotropism
di: Madeleine Lachance, et al.
Pubblicazione: (2025)

Mutational Landscape of Ameloblastoma: Analysis of BRAF and Other Key Mutations in Chinese Patients
di: Zhu You, et al.
Pubblicazione: (2025)

Response to Imatinib in Metastatic Esophageal Melanoma Harboring a KIT L576P (Exon 11) Mutation After Treatment Failure of Immune Checkpoint Inhibitors: A Case Report
di: Yoshiyuki Matsui, et al.
Pubblicazione: (2025)

Antiviral Activity of the MEK1/2 Inhibitor Trametinib Against Lymphocytic Choriomeningitis Virus
di: Wenting Mao, et al.
Pubblicazione: (2025)